Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 05-Apr-24 4:30 PM View:  | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 03-Apr-24 | Private Sale (Planned) | 10,451 | $4.95 | $51,732.40 | (100%) 10.45K to 0 | |
| 02-Apr-24 4:58 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 02-Apr-24 | Planned Option Sale | 150 | $4.98 | $747.04 | (1%) 10.6K to 10.45K | |
| 02-Apr-24 5:01 PM View: | Stephens Kristin Chief Development Officer | Syros Pharmaceuticals, Inc. (SYRS) | 01-Apr-24 | Payment of Exercise | 4,218 | $5.12 | $21,596.20 | (14%) 29.45K to 25.24K | |
| 02-Apr-24 4:52 PM View: | Chee Conley President & CEO Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Apr-24 | Payment of Exercise | 3,500 | $5.12 | $17,920.00 | (13%) 26.0K to 22.5K | |
| 02-Apr-24 4:58 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 01-Apr-24 | Payment of Exercise | 4,732 | $5.12 | $24,227.80 | (31%) 15.33K to 10.6K | |
| 02-Apr-24 4:54 PM View: | Haas Jason Chief Financial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 01-Apr-24 | Payment of Exercise | 4,732 | $5.12 | $24,227.80 | (16%) 29.28K to 24.55K | |
| 02-Apr-24 4:59 PM View: | Simonian Nancy A Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Apr-24 | Payment of Exercise | 14,052 | $5.12 | $71,946.20 | (10%) 145.71K to 131.66K | |
| 02-Apr-24 4:52 PM View: | Chee Conley President & CEO Director | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-24 | Option Exercise | 13,666 | -- | -- | 111% 12.34K to 26.0K | |
| 02-Apr-24 4:58 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-24 | Option Exercise | 15,333 | -- | -- | 100% 0 to 15.33K | |
| 02-Apr-24 4:54 PM View: | Haas Jason Chief Financial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-24 | Option Exercise | 15,333 | -- | -- | 110% 13.95K to 29.28K | |
| 02-Apr-24 4:59 PM View: | Simonian Nancy A Director | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-24 | Option Exercise | 45,566 | -- | -- | 46% 100.14K to 145.71K | |
| 02-Apr-24 5:01 PM View: | Stephens Kristin Chief Development Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-24 | Option Exercise | 13,666 | -- | -- | 87% 15.79K to 29.45K | |
| 02-Apr-24 4:57 PM View: | Quirk Gerald E Chief Legal & Compliance Offic | Syros Pharmaceuticals, Inc. (SYRS) | 28-Mar-24 | Payment of Exercise | 7,046 | $5.59 | $39,387.10 | (15%) 46.8K to 39.76K | |
| 02-Apr-24 4:57 PM View: | Quirk Gerald E Chief Legal & Compliance Offic | Syros Pharmaceuticals, Inc. (SYRS) | 27-Mar-24 | Option Exercise | 22,500 | -- | -- | 93% 24.3K to 46.8K | |
| 26-Dec-23 5:24 PM View: | Akkaraju Srinivas Director | Syros Pharmaceuticals, Inc. (SYRS) | 21-Dec-23 | Purchase | 904,977 | $4.42 | $4,000,000.00 | 102% 884.11K to 1.79M | |
| 14-Dec-23 4:24 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 12-Dec-23 | Private Sale (Planned) | 6,287 | $4.95 | $31,120.60 | (100%) 6.29K to 0 | |
| 08-Dec-23 4:23 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 06-Dec-23 | Private Sale (Planned) | 6,287 | $3.95 | $24,833.70 | (50%) 12.57K to 6.29K | |
| 02-Nov-23 4:53 PM View: | Haas Jason Chief Financial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 01-Nov-23 | Payment of Exercise | 6,301 | $2.22 | $13,988.20 | (31%) 20.25K to 13.95K | |
| 02-Nov-23 4:52 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 01-Nov-23 | Payment of Exercise | 6,301 | $2.22 | $13,988.20 | (33%) 18.88K to 12.57K | |
| 02-Nov-23 4:52 PM View: | Stephens Kristin Chief Development Officer | Syros Pharmaceuticals, Inc. (SYRS) | 01-Nov-23 | Payment of Exercise | 5,676 | $2.22 | $12,600.70 | (26%) 21.46K to 15.79K | |
| 02-Nov-23 4:54 PM View: | Simonian Nancy A President & CEO Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Nov-23 | Payment of Exercise | 13,401 | $2.22 | $29,750.20 | (12%) 113.55K to 100.14K | |
| 02-Nov-23 4:51 PM View: | Chee Conley Chief Commercial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 01-Nov-23 | Payment of Exercise | 6,004 | $2.22 | $13,328.90 | (33%) 18.34K to 12.34K | |
| 02-Nov-23 4:54 PM View: | Simonian Nancy A President & CEO Director | Syros Pharmaceuticals, Inc. (SYRS) | 31-Oct-23 | Option Exercise | 40,125 | -- | -- | 55% 73.42K to 113.55K | |
| 02-Nov-23 4:51 PM View: | Chee Conley Chief Commercial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Oct-23 | Option Exercise | 17,000 | -- | -- | 1267% 1.34K to 18.34K | |
| 02-Nov-23 4:53 PM View: | Haas Jason Chief Financial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Oct-23 | Option Exercise | 18,875 | -- | -- | 1371% 1.38K to 20.25K | |
| 02-Nov-23 4:52 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Oct-23 | Option Exercise | 18,875 | -- | -- | 100% 0 to 18.88K | |
| 02-Nov-23 4:52 PM View: | Stephens Kristin Chief Development Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Oct-23 | Option Exercise | 17,000 | -- | -- | 381% 4.46K to 21.46K | |
| 20-Oct-23 4:23 PM View: | Quirk Gerald E Chief Legal & Compliance Offic | Syros Pharmaceuticals, Inc. (SYRS) | 19-Oct-23 | Payment of Exercise | 6,897 | $2.10 | $14,483.70 | (22%) 31.2K to 24.3K | |
| 20-Oct-23 4:23 PM View: | Quirk Gerald E Chief Legal & Compliance Offic | Syros Pharmaceuticals, Inc. (SYRS) | 11-Oct-23 | Option Exercise | 22,500 | -- | -- | 259% 8.7K to 31.2K | |
| 19-Sep-23 4:46 PM View: | Akkaraju Srinivas Director | Syros Pharmaceuticals, Inc. (SYRS) | 16-Sep-23 | Option Exercise | 2,666 | -- | -- | 100% 0 to 2.67K | |
| 19-Sep-23 4:48 PM View: | Young Richard A Director | Syros Pharmaceuticals, Inc. (SYRS) | 16-Sep-23 | Option Exercise | 2,666 | -- | -- | 7% 36.17K to 38.84K | |
| 19-Sep-23 4:47 PM View: | Alles Mark J Director | Syros Pharmaceuticals, Inc. (SYRS) | 16-Sep-23 | Option Exercise | 2,666 | -- | -- | 267% 1.0K to 3.67K | |
| 02-Aug-23 4:21 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Jul-23 | Private Sale (Planned) | 7,348 | $3.95 | $29,024.60 | (100%) 7.35K to 0 | |
| 18-Jul-23 8:27 PM View: | Olson Eric R Chief Scientific Officer | Syros Pharmaceuticals, Inc. (SYRS) | 17-Jul-23 | Market Sale (Planned) | 689 | $3.50 | $2,411.50 | (9%) 7.35K to 6.66K | 3% |
| 02-Jun-23 4:24 PM View: | Eckhardt Sue Gail Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Jun-23 | Grant | 4,000 | -- | -- | 50% 8.0K to 12.0K | |
| 02-Jun-23 4:26 PM View: | Tyson Timothy Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Jun-23 | Grant | 4,000 | -- | -- | 16% 25.19K to 29.19K | |
| 02-Jun-23 4:24 PM View: | Fanucci Marsha Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Jun-23 | Grant | 4,000 | -- | -- | 50% 8.0K to 12.0K | |
| 02-Jun-23 4:26 PM View: | Wirth Peter Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Jun-23 | Grant | 4,000 | -- | -- | 50% 8.0K to 12.0K | |
| 02-Jun-23 4:25 PM View: | Oh Andrew M. Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Jun-23 | Grant | 4,000 | -- | -- | 50% 8.0K to 12.0K | |
| 02-Jun-23 4:27 PM View: | Young Richard A Director | Syros Pharmaceuticals, Inc. (SYRS) | 01-Jun-23 | Grant | 4,000 | -- | -- | 12% 32.17K to 36.17K | |
| 04-Apr-23 6:54 PM View: | Simonian Nancy A President & CEO Director | Syros Pharmaceuticals, Inc. (SYRS) | 03-Apr-23 | Payment of Exercise | 1,852 | $2.58 | $4,778.16 | (2%) 75.27K to 73.42K | |
| 04-Apr-23 6:56 PM View: | Chee Conley Chief Commercial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 03-Apr-23 | Payment of Exercise | 658 | $2.58 | $1,697.64 | (33%) 2.0K to 1.34K | |
| 04-Apr-23 6:54 PM View: | Olson Eric R Chief Scientific Officer | Syros Pharmaceuticals, Inc. (SYRS) | 03-Apr-23 | Payment of Exercise | 623 | $2.58 | $1,607.34 | (8%) 7.97K to 7.35K | |
| 04-Apr-23 6:56 PM View: | Roth David Chief Medical Officer | Syros Pharmaceuticals, Inc. (SYRS) | 03-Apr-23 | Payment of Exercise | 623 | $2.58 | $1,607.34 | (8%) 7.97K to 7.35K | |
| 04-Apr-23 6:57 PM View: | Haas Jason Chief Financial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 03-Apr-23 | Payment of Exercise | 623 | $2.58 | $1,607.34 | (31%) 2.0K to 1.38K | |
| 04-Apr-23 6:55 PM View: | Stephens Kristin Chief Development Officer | Syros Pharmaceuticals, Inc. (SYRS) | 03-Apr-23 | Payment of Exercise | 623 | $2.58 | $1,607.34 | (12%) 5.09K to 4.46K | |
| 04-Apr-23 6:55 PM View: | Stephens Kristin Chief Development Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-23 | Option Exercise | 2,000 | -- | -- | 65% 3.09K to 5.09K | |
| 04-Apr-23 6:54 PM View: | Simonian Nancy A President & CEO Director | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-23 | Option Exercise | 6,000 | -- | -- | 9% 69.27K to 75.27K | |
| 04-Apr-23 6:56 PM View: | Chee Conley Chief Commercial Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-23 | Option Exercise | 2,000 | -- | -- | 100% 0 to 2.0K | |
| 04-Apr-23 6:54 PM View: | Olson Eric R Chief Scientific Officer | Syros Pharmaceuticals, Inc. (SYRS) | 31-Mar-23 | Option Exercise | 2,000 | -- | -- | 33% 5.97K to 7.97K |
